We've had Eyes On the Datroway approval, and the associated removal of REMS requirements for CAR-T Therapeutics, along with a Biocon deal with Regeneron, and Bharat Biotech expansion plans for CGT manufacturing.

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...